XASE · CATX
+2.80% · +$0.0900 · Vol 1.1M
Market closed · last close 4:00 PM ET · price as of 20:00:00 ET
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

PHARMACEUTICAL PREPARATIONS
$3.30
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
CATX
Perspective Therapeutics, Inc.
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

41/ 100
Veridion Score
SELL BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CATX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CATX catalysts
About Perspective Therapeutics, Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2003
Employees
166
Country
US

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.25
Day high
$3.44
Day low
$3.22
Previous close
$3.21
52W high
$5.65
-41.59% from high
52W low
$2.05
35% of range
Market cap
$376.7M
EPS
$-1.0700
Beta
1.15
Shares out
114.2M
Volume
1.1M
0.90× rel vol
Avg volume
1.3M
VWAP
$3.34
Price history computed in-house
1W
+3.12%
1M
+13.40%
3M
-17.09%
1Y
-10.33%
YTD
+20.00%
SMA 50 $3.10 · above
SMA 200 $3.52 · below
52W position 35%

CATX overview

Veridion Score
41
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CATX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CATX Form 4 filings
Public disclosures

Congress activity in CATX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CATX in the cached public ledger.

Federal contracts

CATX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CATX in this window.
Lobbying spend

CATX lobbying filings, year to date.

Registered lobbying filings matched to Perspective Therapeutics, Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CATX in this window.
Loading news for CATX
Analyst ratings
Sovereign unlock shows live analyst consensus for CATX.
Options
Sovereign unlock shows live options positioning for CATX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.